• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

How Common is Unexpected Uterine Cancer at Hysterectomy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Estimated risk of occult uterine cancer unclear and often not based on subtypes
  • Desai et al. (AJOG, 2019) sought to examine the prevalence of occult uterine cancer at hysterectomy for benign indications as well as related risk factors

METHODS:

  • Retrospective Cohort Study
    • New York Statewide Planning and Research Cooperative System (SPARCS) database (2003-2013)
    • New York State Cancer Registry
  • Participants
    • Inpatient or outpatient hysterectomy for benign indications
  • Data analysis
    • Occult cancer definition: Newly diagnosed corpus uteri cancer within 28 days after the index hysterectomy
    • Prevalence of occult uterine cancer was estimated overall and by subtype
    • Developed and validated risk prediction models

RESULTS:

  • 229,536 women were included
  • Prevalence of occult cancer
    • Overall: 0.96% (95% CI, 0.92 to 1.00%)
    • Endometrial carcinoma: 0.75% (95% CI, 0.71 to 0.78%)
    • Uterine sarcoma: 0.22% (95% CI, 0.20 to 0.23%)
    • Leiomyosarcoma: 0.15% (95% CI, 0.13 to 0.17%)
  • Stage
    • 71% of the endometrial carcinomas and 58.0% of the uterine sarcomas were at localized stage
  • Risk for all occult uterine cancer
    • Varied across the age spectrum
      • 18-29 years: 0.10% | ≥75 years: 4.40% 
      • 1.03% prevalence reached in the 50 to 54 year cohort
    • Varied by indication
      • Endometriosis: 0.14% | Uterine fibroids: 0.62% | Postmenopausal bleeding: 8.43%
  • Risk factors for occult uterine cancer included
    • Race/ethnicity
    • Obesity
    • Comorbidity
    • Personal history of malignancy
  • Prediction models incorporating these risk factors had
    • High negative predictive values: 99.8% for endometrial carcinoma | 99.9% for uterine sarcoma
    • Relatively low positive predictive value

CONCLUSION:

  • Overall, approximately 1% of women undergoing hysterectomy for benign indications had occult uterine cancer
  • Prevalence higher than in some previous studies, however those tend to focus on myomectomy not hysterectomy and therefore may be skewed toward a younger, healthier patient population
  • Patient characteristics may be useful and applied to algorithms
    • Risk algorithms in this study performed better for ruling out cancer rather than predicting the presence of an occult malignancy

Learn More – Primary Sources:

Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What is the Proportion of Cancer Attributable to Obesity in the U.S.?
What is the Prevalence of Occult Malignancy During Hysterectomy or Myomectomy for Benign Indications?
What is the Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy with Morcellation?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site